BWG
ONCT

Beta Wealth Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Beta Wealth Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,600
Closed -$17.2K – 110
2023
Q4 		$17.2K Hold
1,600
– – 0.01% 105
2023
Q3 		$9.6K Hold
1,600
– – 0.01% 99
2023
Q2 		$11K Hold
1,600
– – 0.01% 100
2023
Q1 		$25.1K Hold
1,600
– – 0.01% 100
2022
Q4 		$32K Hold
1,600
– – 0.02% 98
2022
Q3 		$29K Hold
1,600
– – 0.02% 89
2022
Q2 		$36K Hold
1,600
– – 0.02% 87
2022
Q1 		$44K Buy
+1,600
New +$58.2K 0.03% 91

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Beta Wealth Group's ONCT Position: Q1 2024 in Review

Beta Wealth Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 1,600 shares — an estimated $17.2K sold.

Beta Wealth Group first reported a position in ONCT in Q1 2022 and held it in 8 quarters. The position peaked at $44K in Q1 2022. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • Beta Wealth Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Beta Wealth Group sold 1,600 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $17.2K.
  • Beta Wealth Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • Beta Wealth Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $44K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Beta Wealth Group's 13F filing for Q1 2024, filed 15 May 2024.